0001575420false06/30Q32021 0001575420 2020-07-01 2021-03-31 0001575420 2021-05-14 0001575420 2021-03-31 0001575420 2020-06-30 0001575420 2021-01-01 2021-03-31 0001575420 2020-01-01 2020-03-31 0001575420 2019-07-01 2020-03-31 0001575420us-gaap:CommonStockMember 2020-06-30 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001575420us-gaap:CommonStockMember 2020-09-30 0001575420us-gaap:CommonStockMember 2020-12-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001575420us-gaap:CommonStockMember 2019-06-30 0001575420us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001575420us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001575420 2019-07-01 2019-09-30 0001575420us-gaap:CommonStockMember 2019-09-30 0001575420us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001575420us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001575420 2019-10-01 2019-12-31 0001575420us-gaap:CommonStockMember 2019-12-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-06-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-09-30 0001575420 2020-09-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-12-31 0001575420 2020-12-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-06-30 0001575420 2019-06-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-09-30 0001575420 2019-09-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-12-31 0001575420 2019-12-31 0001575420 2020-07-01 2020-09-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-10-01 2020-12-31 0001575420 2020-10-01 2020-12-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-07-01 2019-09-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-10-01 2019-12-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-03-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001575420us-gaap:CommonStockMember 2021-03-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-01-01 2021-03-31 0001575420us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-01-01 2020-03-31 0001575420 2020-03-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-03-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001575420us-gaap:CommonStockMember 2020-03-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001575420us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001575420us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-07-01 2020-09-30 0001575420us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001575420us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001575420us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001575420us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001575420us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001575420us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001575420biio:DigitalDiagnosticsAgMemberbiio:ShareExchangeAgreementMember 2020-09-15 2020-10-07 0001575420biio:EvergreenSolutionsLtdMember 2020-09-15 2020-10-07 0001575420biio:November12016Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:November12016Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:June302017Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:June302017Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:April120181Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:April120181Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:April120182Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:April120182Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:July520181Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:July520181Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:July520182Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:July520182Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:July520183Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:July520183Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:December312018Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:December312018Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:March312019Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:March312019Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:June302019Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:September302019Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:September302019Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:December312019Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:December312019Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:March312020Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:March312020Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:June302020Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:June302020Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:April120181And2Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:July520181Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:January282020Memberus-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-01-28 0001575420biio:EvergreenSolutionsLtdMember 2020-01-01 2020-01-28 0001575420biio:June302018Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:June302018Memberus-gaap:ConvertibleNotesPayableMember 2020-06-30 0001575420biio:November12016Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420srt:MinimumMemberbiio:January282020Memberus-gaap:ConvertibleNotesPayableMember 2020-01-28 0001575420srt:MaximumMemberbiio:January282020Memberus-gaap:ConvertibleNotesPayableMember 2020-01-28 0001575420biio:June302019Memberus-gaap:ConvertibleNotesPayableMember 2021-03-31 0001575420biio:June302017Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:June302018Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:December312018Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:March312019Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:June302019Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:September302019Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:December312019Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:March312020Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:June302020Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420biio:April120181And2Memberus-gaap:ConvertibleNotesPayableMember 2020-07-01 2021-03-31 0001575420srt:MinimumMemberbiio:January282020Memberus-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-01-28 0001575420srt:MaximumMemberbiio:January282020Memberus-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-01-28 0001575420biio:SoleOfficerMember 2020-07-01 2021-03-31 0001575420us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 xbrli:pure xbrli:shares iso4217:USD iso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

~~December~~March 31, ~~2020~~2021

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________________ to _____________________

Commission File Number

333-188152

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Nevada		33-1229553
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

Gewerbestrasse 10, Cham, Switzerland		6330
(Address of principal executive offices)		(Zip Code)

(646)224-1160

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ ~~YES~~Yes ☐ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ ~~YES~~Yes ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES ☒ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

4520,603,598 common shares issued and outstanding as of ~~January~~May 2214, 2021.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition or Plan of Operation	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.	Controls and Procedures	18

PART II - OTHER INFORMATION		19
Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	20
SIGNATURES		21

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Bionovate Technologies Corp

BALANCE SHEETS

(Unaudited)

	December 31,			June 30,
	March 31,			June 30,
	2020			2020
	2021			2020
ASSETS
Current Assets
Cash	$	-—		$	-—
Total Current Assets		-—			-—
TOTAL ASSETS	$	-—		$	-—
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	~~251~~252,~~130~~554		$	211,290
Due to related party		1545,~~468~~709			-—
Convertible notes payable		185,375			185,375
Total Current Liabilities		~~451~~483,~~973~~638			396,665
TOTAL LIABILITIES		~~451~~483,~~973~~638			396,665
Stockholders' Deficit
Preferred stock: 90,000,000 authorized; $0.0001 par value - no shares issued and outstanding		-—			-—
Common stock: 100,000,000 authorized; $0.0001 par value
45,603,598 and 59,423,598 shares issued and outstanding		4,560			5,942
Additional paid in capital		2,297,015			2,295,633
Accumulated deficit		(2,~~753~~785,~~548~~213	)		(2,698,240	)
Total Deficit		(~~451~~483,~~973~~638	)		(396,665	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	-—		$	-—

The accompanying notes are an integral part of these unaudited financial statements

3 ~~Table of Contents~~

~~Bionovate~~Table ~~Technologies~~of ~~Corp~~Contents

~~STATEMENT~~Bionovate OFTechnologies ~~OPERATIONS~~Corp

~~(Unaudited)~~STATEMENT OF OPERATIONS

	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2020			2019			2020			2019
Revenues	$	-		$	-		$	-		$	-
Operating Expenses
General and administration		850			-			850			-
Professional		19,838			10,950			23,460			24,362
Total operating expenses		20,688			10,950			24,310			24,362
Net loss from operations		(20,688	)		(10,950	)		(24,310	)		(24,362	)
Other income (expense)
Realized foreign currency gain (loss)		(282	)		(175	)		(282	)		(107	)
Interest expense		(11,464	)		(34,444	)		(30,716	)		(50,476	)
Total other expense		(11,746	)		(34,619	)		(30,998	)		(50,583	)
Net loss before taxes		(32,434	)		(45,569	)		(55,308	)		(74,945	)
Net loss	$	(32,434	)	$	(45,569	)	$	(55,308	)	$	(74,945	)
Basic and dilutive loss per share
Net loss	$	(0.00	)	$	(0.29	)	$	(0.00	)	$	(0.48	)
Weighted average number of shares outstanding		56,869,902			155,798			58,146,750			155,798

(Unaudited)

The accompanying notes are an integral part of these unaudited financial statements

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2021			2020			2021			2020

Revenues	$	—		$	—		$	—		$	—

Operating Expenses
General and administration		—			—			850			—
Professional fees		16,685			2,748			40,145			27,110
Total operating expenses		16,685			2,748			40,995			27,110

Net loss from operations		(16,685	)		(2,748	)		(40,995	)		(27,110	)

Other income (expense)
Realized foreign currency gain (loss)		46			210			(236	)		103
Interest expense		(15,026	)		(21,600	)		(45,742	)		(72,076	)
Total other expense		(14,980	)		(21,390	)		(45,978	)		(71,973	)

Net loss before taxes		(31,665	)		(24,138	)		(86,973	)		(99,083	)

Net loss	$	(31,665	)	$	(24,138	)	$	(86,973	)	$	(99,083	)

Basic and dilutive loss per share
Net loss	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)
Weighted average number of shares outstanding		45,603,598			40,520,545			54,026,737			13,512,860

4The ~~Table~~accompanying notes are an integral part of ~~Contents~~these unaudited financial statements

~~Bionovate Technologies Corp~~4

~~STATEMENT~~Table OFof ~~STOCKHOLDERS’ DEFICIENCY~~Contents

~~(Unaudited)~~Bionovate Technologies Corp

~~For~~STATEMENT ~~the~~OF ~~Three~~STOCKHOLDERS’ ~~and Six Months Ended December 31, 2020~~DEFICIENCY

							Additional
	Common Stock						Paid in		Accumulated
	Shares			Amount			Capital		Deficit			Total
Balance, June 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,698,240	)	$	(396,665	)
Net loss		-			-			-		(22,874	)		(22,874	)
Balance, September 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,721,114	)	$	(419,539	)
Cancellation of shares		(13,820,000	)		(1,382	)		1,382		-			-
Net loss		-			-			-		(32,434	)		(32,434	)
Balance, December 31, 2020		45,603,598		$	4,560		$	2,297,015	$	(2,753,548	)	$	(451,973	)

(Unaudited)

5For ~~Table~~the ofThree ~~Contents~~and Nine Months Ended March 31, 2021

For the Three and Six Months Ended December 31, 2019

							Additional
	Common Stock						Paid in		Accumulated
	Shares			Amount			Capital		Deficit			Total

Balance, June 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,698,240	)	$	(396,665	)

Net loss		—			—			—		(22,874	)		(22,874	)

Balance, September 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,721,114	)	$	(419,539	)

Cancellation of shares		(13,820,000	)		(1,382	)		1,382		—			—
Net loss		—			—			—		(32,434	)		(32,434	)

Balance, December 31, 2020		45,603,598		$	4,560		$	2,297,015	$	(2,753,548	)	$	(451,973	)

Net loss		—			—			—		(31,665	)		(31,665	)

Balance, March 31, 2021		45,603,598		$	4,560		$	2,297,015	$	(2,785,213	)	$	(483,638	)

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, June 30, 2019		155,798	$	15	$	2,243,891	$	(2,576,195	)	$	(332,289	)
Beneficial conversion feature		-		-		526		-			526
Net loss		-		-		-		(29,376	)		(29,376	)
Balance, September 30, 2019		155,798	$	15	$	2,244,417	$	(2,605,571	)	$	(361,139	)
Beneficial conversion feature		-		-		18,892		-			18,892
Net loss		-		-		-		(45,569	)		(45,569	)
Balance, December 31, 2019		155,798	$	15	$	2,263,309	$	(2,651,140	)	$	(387,816	)

~~The~~Table ~~accompanying notes are an integral part~~ of ~~these unaudited financial statements~~Contents

6For ~~Table~~the ofNine ~~Contents~~Months Ended March 31, 2020

Bionovate Technologies Corp

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total

Balance, June 30, 2019		155,798	$	15	$	2,243,891	$	(2,576,195	)	$	(332,289	)

Beneficial conversion feature		—		—		526		—			526
Net loss		—		—		—		(29,376	)		(29,376	)

Balance, September 30, 2019		155,798	$	15	$	2,244,417	$	(2,605,571	)	$	(361,139	)

Beneficial conversion feature		—		—		18,892		—			18,892
Net loss		—		—		—		(45,569	)		(45,569	)

Balance, December 31, 2019		155,798	$	15	$	2,263,309	$	(2,651,140	)	$	(387,816	)

Common shares issued for conversion of debt		59,267,800		5,927		24,490		—			30,417
Beneficial conversion feature		—		—		5,834		—			5,834
Net loss		—		—		—		(24,138	)		(24,138	)

Balance, March 31, 2020		59,423,598	$	5,942	$	2,293,633	$	(2,675,278	)	$	(375,703	)

~~STATEMENT~~The OFaccompanying ~~CASH~~notes ~~FLOWS~~are an integral part of these unaudited financial statements

~~(Unaudited)~~6

	Six Months Ended
	December 31,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(55,308	)	$	(74,945	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Expenses paid by convertible notes		-			19,418
Expenses paid by related party		15,468			-
Amortization of debt discount		-			19,418
Foreign currency adjustment		282			107
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		39,558			36,002
Net cash provided by operating activities		-			-
Net change in cash and cash equivalents		-			-
Cash and cash equivalents, beginning of period		-			-
Cash and cash equivalents, end of period	$	-		$	-
Supplemental cash flow information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-cash transactions:
Beneficial conversion feature	$	-		$	19,418
Cancellation of shares	$	1,382		$	-

Table of Contents

~~The~~Bionovate ~~accompanying~~Technologies ~~notes are an integral part of these unaudited financial statements~~Corp

7STATEMENT ~~Table~~OF ofCASH ~~Contents~~FLOWS

~~Bionovate Technologies Corp~~(Unaudited)

NOTES TO THE FINANCIAL STATEMENTS

	Nine Months Ended
	March 31,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(86,973	)	$	(99,083	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Expenses paid by convertible notes		—			25,252
Expenses paid by related party		45,709			—
Amortization of debt discount		—			25,252
Foreign currency adjustment		236			(103	)
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		41,028			48,682
Net cash provided by operating activities		—			—

Net change in cash and cash equivalents		—			—
Cash, beginning of period		—			—
Cash, end of period	$	—		$	—

Supplemental cash flow information
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—

Non-cash transactions:
Beneficial conversion feature	$	—		$	25,252
Cancellation of shares	$	1,382		$	—
Common stock issued for conversion of debt	$	—		$	30,417

~~December~~The ~~31,~~accompanying ~~2020~~notes are an integral part of these unaudited financial statements

~~NOTE 1 – NATURE AND CONTINUANCE OF OPERATIONS~~7

~~Bionovate~~Table ~~Technologies Corp. (the “Company”, or the “Corporation”) was incorporated in the state~~ of ~~Nevada, United States on October 24, 2012 under the name MJP International Ltd. On December 1, 2017, the Company’s corporate name was changed to Bionovate Technologies Corp.~~Contents

~~The~~Bionovate ~~Corporation~~Technologies was formed and organized to capitalize on new opportunities found in the North American market for light-emitting diode (“LED”) lighting. With China as the manufacturing backbone of future LED products, the Corporation has set up an office in Guangzhou, China in search of high-quality products offered by reputable manufacturers to be introduced to Canada, the United States, and abroad. The Corporation has set out further details of the acquisition below as well as in Notes 3 and 4 to these consolidated financial statements.Corp

~~Bionovate~~NOTES ~~Technologies~~TO ~~Corp.~~THE ~~focuses~~FINANCIAL on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device. STATEMENTS

OnMarch ~~October 7~~31, 2020, Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions, Ltd, a private Company (“Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”).2021

~~Pursuant~~NOTE to1 ~~the Share Exchange Agreement, in exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to wit,~~– ~~54,270,000 shares~~NATURE ~~(the~~AND ~~“Exchange~~CONTINUANCE ~~Shares”),~~OF ~~the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital.~~OPERATIONS

~~The~~Bionovate ~~Share~~Technologies ~~Exchange~~Corp. ~~Agreement contains customary representations and warranties made by~~ (the “Company”, onor the ~~one~~“Corporation”) ~~hand,~~was ~~and~~incorporated ~~Evergreen~~in ~~and Human Data on~~ the ~~other~~state ~~hand~~of Nevada, ~~made~~United ~~solely~~States ~~for~~on ~~the~~October ~~benefit of the other~~24, ~~which~~2012 inunder ~~certain~~the ~~cases~~name ~~are~~MJP ~~subject~~International toLtd. ~~specified~~On ~~exceptions~~December ~~and~~1, ~~qualifications~~2017, ~~contained in~~ the ~~Share~~Company’s ~~Exchange~~corporate ~~Agreement~~name orwas inchanged ~~information provided pursuant~~ to ~~certain~~Bionovate ~~disclosure~~Technologies ~~schedules to the Share Exchange Agreement~~Corp.

The ~~share~~Corporation ~~exchange~~was ~~agreement~~formed ~~gave~~and organized to capitalize on new opportunities found in the ~~other~~North ~~party~~American 90market ~~days~~for tolight-emitting ~~transfer~~diode ~~shares~~(“LED”) lighting. With China as the manufacturing backbone of ~~Digital~~future toLED ~~Bionovate.~~products, ~~Bionovate~~the ~~did~~Corporation ~~not~~has ~~receive~~set ~~these~~up ~~shares~~an ~~yet~~office ~~and~~in ~~does~~Guangzhou, ~~not~~China ~~own~~in ~~any~~search of ~~Digital~~high-quality ~~Diagnostics~~products asoffered ofby reputable manufacturers to be introduced to Canada, the ~~date~~United States, and abroad. The Corporation has set out further details of ~~this~~the ~~report~~acquisition below as well as in Notes 3 and 4 to these consolidated financial statements.

~~GOING~~Bionovate ~~CONCERN~~Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device.

~~The~~On ~~accompanying~~October ~~financial~~7, ~~statements have been prepared in conformity with accounting principles generally accepted in the United States of America~~2020, ~~which~~Bionovate ~~contemplate~~Technologies ~~continuation~~Corp. of (the “Company”) asentered into a ~~going~~Share ~~concern.~~Exchange ~~However,~~Agreement (the ~~Company~~“Share ~~has~~Exchange anAgreement”) ~~accumulated~~facilitated ~~deficit~~between atEvergreen ~~December 31~~Solutions, ~~2020 of $2~~Ltd,~~753,548,~~ ~~is in~~ a ~~net~~private ~~liability~~Company ~~position~~(“Evergreen”), and ~~needs~~Human ~~cash~~Data toAG, ~~maintain~~a ~~its~~private ~~operations~~Switzerland Company (“Human Data”).

~~These~~Pursuant ~~factors~~to ~~raise substantial doubt about~~ the ~~Company’s~~Share ~~ability~~Exchange toAgreement, ~~continue~~in asexchange afor ~~going concern. The accompanying financial statements do not include any adjustments that might result from~~ the ~~outcome~~acquisition of ~~this~~all ~~uncertainty.~~of ~~The~~the outstanding Company’s ~~continued~~shares ~~existence~~which isEvergreen ~~dependent~~owns, ~~upon management’s ability~~ to ~~develop profitable operations~~wit, 54,270,000 shares ~~continued~~(the ~~contributions~~“Exchange ~~from~~Shares”), the Company’s ~~executive~~will ~~officers~~receive 12,500 shares toof ~~finance~~Digital ~~its~~Diagnostics ~~operations~~AG ~~and~~(“Digital”) ~~the~~owned ~~ability~~by toHuman ~~obtain~~Data, ~~additional~~which ~~funding~~equates ~~sources~~ to 25% ~~explore~~of ~~potential strategic relationships and to provide capital and other resources for~~ the ~~further~~currently ~~development~~issued ~~and~~shares ~~marketing~~ of ~~the Company’s products and business~~Digital.

~~NOTE~~The 2–Share ~~SUMMARY~~Exchange OFAgreement ~~SIGNIFICANT~~contains ~~ACCOUNTING~~customary ~~POLICIES~~representations and warranties made by the Company, on the one hand, and Evergreen and Human Data on the other hand, made solely for the benefit of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement

~~Basis~~The share exchange agreement gave the other party 90 days to transfer shares of ~~Presentation~~Digital to Bionovate. Bionovate did not receive these shares yet and does not own any of Digital Diagnostics as of the date of this report.

~~The~~GOING accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three months ended December 31, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the financial statements and footnotes thereto included in the Corporation’s filed Form 10-K for the year ended June 30, 2020.CONCERN

8The ~~Table~~accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of ~~Contents~~America, which contemplate continuation of the Company as a going concern. However, the Company has an accumulated deficit at March 31, 2021 of $2,785,213, is in a net liability position and needs cash to maintain its operations.

~~The~~These ~~preparation~~factors ofraise ~~financial~~substantial ~~statements~~doubt inabout ~~conformity~~the ~~with~~Company’s ~~U.S.~~ability ~~GAAP requires management~~ to ~~make~~continue ~~estimates~~as ~~and~~a ~~assumptions~~going ~~that~~concern. ~~affect~~The ~~application~~accompanying ~~of policies and the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the~~ financial statements ~~and~~do ~~the~~not ~~reported~~include ~~amounts~~any ofadjustments ~~revenues~~that ~~and~~might ~~expenses~~result ~~during~~from the ~~year.~~outcome ~~Actual~~of ~~results~~this ~~could differ from these estimates~~uncertainty. ~~Estimates~~The ~~and~~Company’s ~~their~~continued ~~underlying~~existence ~~assumptions~~is ~~are~~dependent ~~reviewed~~upon onmanagement’s anability ~~ongoing~~to ~~basis.~~develop ~~Changes~~profitable inoperations, ~~estimates~~continued ~~are~~contributions ~~recorded~~from in the ~~accounting~~Company’s ~~period~~executive inofficers ~~which~~to ~~they~~finance ~~are~~its ~~determined.~~operations ~~The critical accounting estimates~~ and ~~assumptions in~~ the ~~accompanying~~ability ~~unaudited~~to ~~condensed~~obtain ~~interim~~additional ~~financial~~funding ~~statements~~sources ~~include~~to ~~the~~explore ~~provision~~potential ~~for~~strategic ~~unpaid~~relationships ~~loss~~ and ~~loss~~to ~~adjustment~~provide ~~expenses~~capital ~~which~~and ~~may~~other ~~result~~resources ~~from~~for ~~product~~the ~~warranty~~further ~~provisions;~~development ~~valuation of deferred income taxes; valuation~~ and ~~impairment~~marketing ~~assessment~~ of ~~intangible~~the ~~assets;~~Company’s ~~goodwill~~products ~~recoverability;~~ and ~~deferred acquisition costs~~business.

~~Fair Value of Financial Instrument~~8

~~The~~Table Corporation follows FASB ASC 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Corporation defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.Contents

~~When~~NOTE ~~determining~~2– ~~the~~SUMMARY ~~fair~~OF ~~value~~SIGNIFICANT ~~measurements~~ACCOUNTING for assets and liabilities, which are required to be recorded at fair value, the Corporation considers the principal or most advantageous market in which the Corporation would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.POLICIES

~~The~~Basis ~~Corporation~~of applies FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Corporation has not elected the fair value option for any eligible financial instruments.Presentation

~~Basic~~The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and ~~Diluted~~with ~~Loss~~the ~~per~~instructions ~~Common~~for ~~Stock~~Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the nine months ended March 31, 2021, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the financial statements and footnotes thereto included in the Corporation’s filed Form 10-K for the year ended June 30, 2020.

~~FASB~~The ~~ASC~~preparation ~~260~~of financial statements in conformity with U.S. GAAP requires ~~dual~~management ~~presentation~~to ofmake ~~basic~~estimates and ~~diluted~~assumptions ~~earnings~~that ~~per~~affect ~~share~~application ~~(EPS)~~of ~~with~~policies aand ~~reconciliation~~the reported amounts of ~~the~~assets ~~numerator~~and liabilities and ~~denominator~~disclosure of contingent assets and liabilities at the ~~EPS~~date ~~computations.~~of ~~Basic~~the ~~earnings~~financial ~~per~~statements ~~share~~and the reported amounts ~~are~~of ~~based~~revenues onand expenses during the ~~weighted~~year. ~~average~~Actual ~~shares~~results ofcould ~~common~~differ ~~stock~~from ~~outstanding~~these estimates. IfEstimates ~~applicable,~~and ~~diluted~~their ~~earnings~~underlying ~~per~~assumptions ~~stock~~are ~~would~~reviewed ~~assume~~on ~~the~~an ~~conversion,~~ongoing ~~exercise~~basis. orChanges ~~issuance~~in ofestimates ~~all~~are ~~potential~~recorded ~~common~~in ~~stock~~the ~~instruments~~accounting ~~such~~period asin ~~options,~~which ~~warrants~~they are determined. The critical accounting estimates and ~~convertible~~assumptions ~~securities,~~in ~~unless~~the accompanying unaudited condensed interim financial statements include the ~~effect~~provision isfor tounpaid ~~reduce~~loss aand loss oradjustment ~~increase~~expenses ~~earnings~~which ~~per~~may ~~share.~~result ~~Diluted~~from ~~net~~product ~~income~~warranty ~~(loss)~~provisions; ~~per~~valuation ~~common~~of ~~stock~~deferred onincome ~~the~~taxes; ~~potential~~valuation ~~exercise~~and ofimpairment ~~the~~assessment ~~equity-based~~of ~~financial~~intangible ~~instruments~~assets; isgoodwill ~~not~~recoverability; ~~presented~~and ~~where~~deferred ~~anti-dilutive~~acquisition costs.

~~For~~Fair ~~the~~Value ~~six months ended December 31, 2020 and 2019, the following common stock equivalents were excluded from the computation~~ of ~~diluted~~Financial ~~net loss per share as the result of the computation was anti-dilutive.~~Instrument

	December 31,		December 31,
	2020		2019
	(shares)		(shares)
Convertible notes		26,740,500		27,544,200

The Corporation follows FASB ASC 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Corporation defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

~~NOTE~~When 3determining –the ~~ACCOUNTS~~fair ~~PAYABLE~~value ~~AND~~measurements ~~ACCRUED~~for ~~LIABILITEIS~~assets and liabilities, which are required to be recorded at fair value, the Corporation considers the principal or most advantageous market in which the Corporation would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

AsThe ofCorporation ~~December~~applies 31FASB ASC 825, ~~2020~~Financial Instruments, ~~and~~which ~~June~~allows ~~30,~~companies ~~2020,~~to ~~accounts~~choose ~~payable~~to measure eligible financial instruments and ~~accrued~~certain ~~liabilities~~other ~~consisted~~items ofat asfair ~~follows,~~value that are not required to be measured at fair value. The Corporation has not elected the fair value option for any eligible financial instruments.

	December 31,		June 30,
	2020		2020
Accounts payable	$	47,479	$	25,702
Accrued expense		-		12,654
Accrued interest		162,626		131,909
Due to a former related party		41,025		41,025
	$	251,130	$	211,290

Basic and Diluted Loss per Common Stock

9FASB ~~Table~~ASC 260 requires dual presentation of ~~Contents~~basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per stock would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per common stock on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive.

~~NOTE 4 – CONVERTIBLE NOTE~~9

~~Convertible~~Table ~~notes payable at December 31, 2020 and June 30,2020, consists~~ of ~~the following:~~Contents

	December 31,		June 30,
	2020		2020
Dated November 1, 2016	$	4,439	$	4,439
Dated June 30, 2017		9,969		9,969
Dated April 1, 2018 - 1		10,000		10,000
Dated April 1, 2018 - 2		10,000		10,000
Dated June 30, 2018		28,376		28,376
Dated July 5, 2018 - 1		30,000		30,000
Dated July 5, 2018 - 2		15,000		15,000
Dated July 5, 2018 - 3		15,000		15,000
Dated December 31, 2018		17,302		17,302
Dated March 31, 2019		1,000		1,000
Dated June 30, 2019		17,037		17,037
Dated September 30, 2019		526		526
Dated December 31, 2019		18,892		18,892
Dated March 31, 2020		5,834		5,834
Dated June 30, 2020		2,000		2,000
Total convertible notes payable		185,375		185,375
Less: Unamortized debt discount		-		-
Total convertible notes		185,375		185,375
Less: current portion of convertible notes		185,375		185,375
Long-term convertible notes	$	-	$	-

For the nine months ended March 31, 2021 and 2020, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

For the six months ended December 31, 2020 and 2019, the Company recognized interest expense of $30,716 and $31,058 and amortization of discount, included in interest expense, of $0 and $19,418, respectively. As of December 31, 2020, and June 30, 2020, the Company recorded accrued interest of $162,626 and $131,909, respectively.

	March 31,		March 31,
	2021		2020
	(shares)		(shares)
Convertible notes		26,740,500		24,740,500

~~Dated~~NOTE ~~November~~3 1,– ~~2016~~ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS

OnAs ~~November 1, 2016, the Company issued a convertible note with a conversion price~~ of ~~$0.005~~March ~~to extinguish debt of $18~~31,~~239.~~ ~~The convertible note is unsecured~~2021, ~~bears interest at 4% per annum~~ and ~~due~~June ~~and~~30, ~~payable on November 1~~2020, ~~2017.~~accounts ~~The~~payable ~~Company~~and ~~recorded~~accrued aliabilities ~~discount~~consisted ~~on the convertible note due to a beneficial conversion feature~~ of ~~$18~~as follows,~~239.~~

Dated June 30, 2017

	March 31,		June 30,
	2021		2020
Accounts payable	$	33,878	$	25,702
Accrued expense		—		12,654
Accrued interest		177,651		131,909
Due to a former related party		41,025		41,025
	$	252,554	$	211,290

OnNOTE ~~June~~4 ~~30,~~– ~~2017,~~CONVERTIBLE the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $9,969. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $9,969.NOTE

10Convertible ~~Table~~notes payable at March 31, 2021 and June 30,2020, consists of ~~Contents~~the following:

Dated April 1, 2018 – 1 and 2

	March 31,		June 30,
	2021		2020
Dated November 1, 2016	$	4,439	$	4,439
Dated June 30, 2017		9,969		9,969
Dated April 1, 2018 - 1		10,000		10,000
Dated April 1, 2018 - 2		10,000		10,000
Dated June 30, 2018		28,376		28,376
Dated July 5, 2018 - 1		30,000		30,000
Dated July 5, 2018 - 2		15,000		15,000
Dated July 5, 2018 - 3		15,000		15,000
Dated December 31, 2018		17,302		17,302
Dated March 31, 2019		1,000		1,000
Dated June 30, 2019		17,037		17,037
Dated September 30, 2019		526		526
Dated December 31, 2019		18,892		18,892
Dated March 31, 2020		5,834		5,834
Dated June 30, 2020		2,000		2,000
Total convertible notes payable		185,375		185,375

Less: Unamortized debt discount		—		—
Total convertible notes		185,375		185,375

Less: current portion of convertible notes		185,375		185,375
Long-term convertible notes	$	—	$	—

OnFor ~~April~~the 1nine months ended March 31, ~~2018~~2021 and 2020, the Company ~~issued~~recognized 2interest ~~convertible~~expense ~~notes totaling~~ of $2045,~~000~~742 ~~with~~and a$46,824 ~~conversion~~and ~~price~~amortization of ~~$$0.01~~discount, toincluded ~~pay~~in ainterest ~~purchase~~expense, of a$0 ~~patent~~and of $1025,~~000~~252, respectively. ~~The~~As ~~convertible~~of ~~note~~March ~~is unsecured~~31, ~~bears interest at 45% per annum~~2021, ~~has no maturity date~~ and isJune ~~due~~30, on2020, ~~demand.~~the ~~The~~ Company recorded aaccrued ~~discount~~interest onof ~~the~~$177,651 ~~convertible~~and ~~note due to a beneficial conversion feature of~~ $20131,~~000~~909, respectively.

~~Dated June 30, 2018~~10

OnTable ~~June 30, 2018, the Company issued a convertible note with a conversion price~~ of $0.01 to pay operating expenses of $28,376. The convertible note is unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $28,376.Contents

Dated ~~July~~November ~~5, 2018 –~~ 1, ~~2 and 3~~2016

On ~~June~~November 301, ~~2018~~2016, the Company issued 3a convertible ~~notes~~note ~~totaling of $60,000~~ with a conversion price of $0.01005 to extinguish ~~amounts~~debt ~~due to related parties~~ of $~~145~~18,~~523~~239. The convertible ~~notes~~note ~~are~~is unsecured, bears interest at 304% per annum, ~~has~~and nodue ~~maturity date~~ and ispayable ~~due~~ on ~~demand~~November 1, 2017. The Company recorded a discount on the convertible ~~notes~~note due to a beneficial conversion feature of $6018,~~000~~239.

Dated ~~December~~June 3130, ~~2018~~2017

On ~~December~~June 3130, ~~2018~~2017, the Company issued a convertible note with a conversion price of $0.~~005~~01 to pay operating expenses of $179,~~302~~969. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible ~~notes~~note due to a beneficial conversion feature of $179,~~302~~969.

Dated ~~March~~April 311, ~~2019~~2018 – 1 and 2

On ~~March~~April 311, ~~2019~~2018, the Company issued a2 convertible ~~note~~notes totaling of $20,000 with a conversion price of $0.01 to pay ~~operating~~a ~~expenses~~purchase of a patent of $610,~~427~~000. The convertible note is unsecured, bears interest at 2045% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible ~~notes~~note due to a beneficial conversion feature of $620,~~427~~000.

~~Effective~~Dated ~~January~~June 2830, ~~2020, the Company amended a convertible note. The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.~~2018

~~Effective~~On ~~January~~June 2830, ~~2020~~2018, the ~~Note~~Company issued a convertible note with a conversion price of $~~6,427~~0.01 ~~was~~to ~~assigned~~pay tooperating ~~Evergreen~~expenses ~~Solutions~~of ~~Ltd~~$28,376. The convertible note is unsecured, ~~and~~bears $5interest at 30% per annum,~~427~~ ~~was~~has ~~immediately~~no ~~converted~~maturity ~~for~~date ~~the~~and ~~issuance~~is ofdue ~~54,270,000~~on ~~shares~~demand. ofThe ~~common~~Company ~~stock~~recorded ofa discount on the ~~Company~~convertible ~~resulting~~note indue to a ~~change~~beneficial conversion feature of ~~control~~$28,376.

Dated ~~June~~July 305, ~~2019~~2018 – 1, 2 and 3

On June 30, ~~2019~~2018, the Company issued a3 convertible ~~note~~notes totaling of $60,000 with a conversion price of $0.~~005~~01 to ~~pay~~extinguish ~~operating~~amounts ~~expenses~~due to related parties of $17145,~~037~~523. The convertible ~~note~~notes isare unsecured, bears interest at 3530% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $1760,~~037~~000.

Dated ~~September~~December 3031, ~~2019~~2018

On ~~September~~December 3031, ~~2019~~2018, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $~~526~~17,302. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $~~526~~17,302.

Dated ~~December~~March 31, 2019

On ~~December~~March 31, 2019, the Company issued a convertible note with a conversion price of $0.~~005~~01 to pay operating expenses of $186,~~892~~427. The convertible note is unsecured, bears interest at 3520% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $186,~~892~~427.

11Effective ~~Table~~January of28, ~~Contents~~2020, the Company amended a convertible note. The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.

~~Dated~~Effective ~~March~~January 3128, 2020, the Note of $6,427 was assigned to Evergreen Solutions Ltd., and $5,427 was immediately converted for the issuance of 54,270,000 shares of common stock of the Company resulting in a change of control.

On March 31, 2020, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $5,834. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $5,834.11

~~Dated~~Table ~~June~~of ~~30, 2020~~Contents

OnDated June 30, 2020, the Company issued a convertible note with a conversion price of $0.001 to pay operating expenses of $2,000. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $2,000.2019

~~NOTE~~On 5June -30, ~~RELATED~~2019, ~~PARTY~~the ~~TRANSACTIONS~~Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,037. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,037.

~~During~~Dated ~~the~~September ~~six months ended December 31~~30, 2020, the Company’s sole officer paid $15,468 for operating expenses on behalf of the Company. As of December 31, 2020, the Company was obligated to the officer, for an unsecured, non-interest-bearing demand loan with a balance of $15,468.2019

~~NOTE~~On 6September –30, ~~EQUITY~~2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $526. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $526.

~~Preferred~~Dated ~~Stock~~December 31, 2019

~~The~~On December 31, 2019, the Company isissued ~~authorized~~a convertible note with a conversion price of $0.005 to ~~issue~~pay ~~90,000,000~~operating ~~shares~~expenses of ~~preferred~~$18,892. ~~stock~~The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a ~~par~~discount ~~value~~on the convertible notes due to a beneficial conversion feature of $018,892.~~0001.~~

NoDated ~~shares~~March ~~were issued and outstanding as of December~~ 31, 2020 ~~and June 30,2020, respectively.~~

~~Common~~On ~~Stock~~March 31, 2020, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $5,834. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $5,834.

~~The~~Dated ~~Company~~June ~~is authorized to issue 100~~30,~~000,000~~ ~~shares of preferred stock at a par value of $0.0001.~~2020

~~During~~On June 30, 2020, the ~~six~~Company ~~months~~issued ~~ended~~a ~~December~~convertible 31note with a conversion price of $0.001 to pay operating expenses of $2,000. ~~2020~~The convertible note is unsecured, 13bears interest at 35% per annum,~~820,000~~ ~~shares~~has ~~were~~no ~~canceled~~maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $2,000.

AsNOTE of5 ~~December~~- ~~31,~~RELATED ~~2020~~PARTY ~~and June 30, 2020, 45,603,598 and 59,423,598 shares of common stock were issued and outstanding.~~TRANSACTIONS

During the nine months ended March 31, 2021, the Company’s sole officer paid $45,709 for operating expenses on behalf of the Company. As of ~~December~~March 31, ~~2020~~2021, ~~there~~the ~~were~~Company nowas ~~warrants~~obligated orto ~~options~~the ~~outstanding~~officer, for an unsecured, non-interest-bearing demand loan with a balance of $45,709.

NOTE 76 – ~~SUBSEQUENT~~ ~~EVENT~~EQUITY

~~Management~~Preferred ~~has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.~~Stock

12The ~~Table~~Company is authorized to issue 90,000,000 shares of ~~Contents~~preferred stock at a par value of $0.0001.

~~Item~~No 2.shares ~~Management’s~~were ~~Discussion~~issued and ~~Analysis~~outstanding as of ~~Financial~~March ~~Condition~~31, or2021 ~~Plan~~and ofJune ~~Operation~~30,2020, respectively.

~~FORWARD-LOOKING~~Common ~~STATEMENTS~~Stock

~~This~~The ~~quarterly~~Company ~~report~~is ~~contains~~authorized ~~forward-looking statements. These statements relate~~ to ~~future~~issue ~~events or our future financial performance. In some cases~~100, ~~you can identify forward-looking statements by terminology such as “may”~~000,000 ~~“should”,~~shares ~~“expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative~~ of ~~these~~common ~~terms~~stock orat ~~other~~a ~~comparable~~par ~~terminology.~~value ~~These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels~~ of ~~activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements~~$0. ~~Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements~~0001. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

~~Our~~During consolidated unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the ~~related~~nine ~~notes~~months ~~that~~ended ~~appear~~March ~~elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans~~31, ~~estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include~~2021, ~~but are not limited to~~13,820,000 ~~those~~shares ~~discussed~~of ~~below~~common ~~and~~stock ~~elsewhere~~were ~~in this quarterly report~~canceled.

~~Unless~~As ~~otherwise~~of ~~specified~~March in31, ~~this quarterly report~~2021, ~~all~~and ~~dollar~~June ~~amounts~~30, ~~are~~2020, ~~expressed~~45,603,598 ~~in United States dollars~~ and ~~all~~59,423,598 ~~references~~shares toof “common stock” ~~refer~~were toissued ~~shares~~and ~~of our common stock~~outstanding.

As ~~used~~of inMarch ~~this quarterly report~~31, ~~the terms “we”~~2021, ~~“us”,~~there ~~“our”~~were ~~and~~no ~~“our~~warrants ~~company”~~or ~~mean~~options ~~Bionovate Technologies Corp~~outstanding.~~, unless otherwise indicated.~~

~~Corporate Overview~~12

~~Our~~Table ~~company was incorporated in the State~~ of Nevada on October 24, 2012. Founded in Calgary, Canada, we were formed and organized to capitalize on new opportunities found in the North American market for light-emitting diode (“LED”) lighting. With China as the manufacturing backbone of future LED products, we have set up an office in Guangzhou, China in search of high quality products offered by reputable manufacturers to be introduced to Canada, the United States, and abroad. In November 2016, we expanded our operations to include reselling various energy products and green technology products. We achieved this by acquiring Energy Alliance Labs Inc. (“Energy Alliance”), which is the 80% owner of Human Energy Alliance Laboratories Corp., an Idaho corporation (“HEAL”). HEAL is a “green technology” and retail company with the mission of developing and distributing technologies that relieve its customers of certain burdens, while simultaneously decreasing the energy they use. HEAL’s primary products are mid-sized wind turbines, small solar panels and related controllers and inverters.Contents

OnNOTE ~~October~~7 ~~28,~~– SUBSEQUENT 2016, we entered into a share exchange agreement with Cohen Mizrahi, a director of our company, whereby on the same date we issued 4,000,000 shares of our common stock in exchange for 100% of the issued and outstanding equity interests of Energy Alliance.EVENT

OnManagement ~~November~~has 1,evaluated ~~2016,~~subsequent ~~Energy~~events ~~Alliance~~through ~~closed~~ the ~~transactions~~date ~~contemplated~~these ~~under~~financial anstatements ~~agreement~~were ~~with~~available ~~certain~~to ~~shareholders~~be ofissued. ~~HEAL,~~Based inon ~~which~~our ~~the~~evaluation ~~shareholders~~no ~~holding~~material ~~80%~~events ofhave ~~the~~occurred ~~outstanding~~that ~~equity~~require ~~interests of HEAL sold all of their shares of HEAL to Energy Alliance~~disclosure.

AsSubsequent ato ~~result~~March of31, ~~such~~2021, ~~transactions~~25,000,000 weshares ~~became~~of ~~the~~common ~~owner~~stock ofwere ~~100%~~returned ofto the ~~issued~~Company ~~and~~by ~~outstanding~~our ~~equity~~major ~~interests~~shareholder ofwho ~~Energy~~is ~~Alliance~~also ~~and~~our ~~Energy~~CEO, ~~Alliance became the owner of 80% of the issued~~ and ~~outstanding equity interests of HEAL~~cancelled.

~~Effective October 4, 2016, we filed a Certificate of Dissolution of MJP Holdings Ltd., our wholly-owned subsidiary.~~13

13 Table of Contents

~~Effective~~ ~~November~~Item ~~28, 2016, we entered into a Share Exchange Agreement with MJP Lighting Solutions Ltd~~2., aManagement’s ~~British~~Discussion ~~Virgin Islands (“BVI”) corporation~~ and ~~Tong~~Analysis ~~Tang and Zhao Hui Ma (the “Shareholders”) whereby the parties exchanged 100%~~ of ~~the~~Financial ~~issued~~Condition ~~and~~or ~~outstanding~~Plan ~~shares~~ of ~~BVI, belonging to our company for the tender of 5,500,000 restricted common shares of our company, belonging to the Shareholders, to our treasury for cancellation.~~Operation

OnFORWARD-LOOKING January 1, 2017, MJP entered into transfer agreement with Cohen Mizrahi, whereby we transferred 100% of the issued and outstanding equity interests of Energy Alliance for consideration of $20,000 for past services provided to our company by Mr. Guo.STATEMENTS

OnThis ~~December~~quarterly 1report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, ~~2017~~you can identify forward-looking statements by terminology such as “may”, a“should”, ~~majority~~“expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of ~~our~~these ~~stockholders~~terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our ~~board~~or ofour ~~directors~~industry’s ~~approved~~actual aresults, ~~change~~levels of ~~name~~activity, ofperformance ~~our~~or ~~company~~achievements to ~~“Bionovate~~be ~~Technologies~~materially ~~Corp~~different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.” ~~and~~Although awe ~~reverse~~believe ~~stock~~that ~~split~~the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of ~~our~~activity, ~~issued~~performance ~~and~~or ~~outstanding~~achievements. ~~shares~~Except as required by applicable law, including the securities laws of ~~common~~the ~~stock~~United onStates, awe ~~fifty~~do ~~(50)~~not ~~old~~intend ~~for~~to ~~one~~update ~~(1)~~any ~~new~~of ~~basis~~the forward-looking statements to conform these statements to actual results.

AOur ~~Certificate~~consolidated ofunaudited ~~Amendment~~financial ~~was~~statements ~~filed~~are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the ~~Nevada~~related ~~Secretary~~notes ofthat ~~State~~appear onelsewhere ~~December~~in 11this quarterly report. The following discussion contains forward-looking statements that reflect our plans, ~~2017~~estimates ~~with~~and anbeliefs. ~~effective~~Our ~~date~~actual ofresults ~~December~~could 21differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, ~~2017~~but are not limited to, those discussed below and elsewhere in this quarterly report.

~~The~~Unless ~~name~~otherwise ~~change~~specified ~~and~~in ~~reverse~~this ~~split~~quarterly ~~became~~report, ~~effective~~all ~~with~~dollar ~~the~~amounts ~~OTC~~are ~~Markets~~expressed atin ~~the~~United ~~opening~~States ofdollars ~~trading~~and onall ~~December~~references ~~21,~~to ~~2017~~“common ~~under~~stock” ~~the~~refer ~~symbol~~to ~~“BIIO”~~shares of our common stock.

~~Effective~~As ~~January~~used ~~11,~~in ~~2018,~~this wequarterly ~~entered~~report, ~~into a Patent Purchase and License Agreement with Lily Innovation Advisors Ltd. wherein we agreed to purchase~~ the ~~rights~~terms ~~to U.S. Patent No. 7~~“we”,~~963,959~~ “~~Automated Cryogenic Skin Treatment~~us”, ~~(the~~ “~~Lily Patent~~our”). ~~We paid $10,000 as consideration for the Lily Patent,~~ and ~~agreed to pay royalties of one percent (1%) of the (a) net sales of all products that are derived from the invention covered under the Lily Patent and sold by~~ “our company” ormean ~~any~~Bionovate ~~licensees~~Technologies ~~or transferees and (b) licensing fees~~Corp., ~~royalties~~unless orotherwise similar payments in respect of the Lily Patent received by any such entity, such royalties to be paid quarterly in January, April, July and October for all sales incurred in the previous calendar quarterindicated.

~~The~~Corporate ~~assignment of the Lily Patent was registered with the United States Patent and Trademark Office on January 31, 2018.~~Overview

~~The~~Our ~~foregoing~~company ~~description~~was ofincorporated in the ~~Patent~~State ~~Purchase~~of ~~and~~Nevada ~~License~~on ~~Agreement~~October is24, ~~included~~2012. Founded in Calgary, Canada, we were formed and organized to ~~provide~~capitalize ~~information~~on ~~regarding~~new ~~its~~opportunities ~~terms~~found in the North American market for light-emitting diode (“LED”) lighting. ItWith ~~does~~China ~~not~~as ~~purport~~the manufacturing backbone of future LED products, we have set up an office in Guangzhou, China in search of high quality products offered by reputable manufacturers to be aintroduced ~~complete~~to ~~description~~Canada, the United States, and isabroad. ~~qualified~~In byNovember ~~its~~2016, ~~entirety~~we byexpanded ~~reference~~our operations to include reselling various energy products and green technology products. We achieved this by acquiring Energy Alliance Labs Inc. (“Energy Alliance”), which is the ~~full~~80% ~~text~~owner of Human Energy Alliance Laboratories Corp., an Idaho corporation (“HEAL”). HEAL is a “green technology” and retail company with the ~~Patent~~mission ~~Purchase~~of developing and ~~License~~distributing ~~Agreement~~technologies that relieve its customers of certain burdens, ~~which~~while issimultaneously ~~filed~~decreasing asthe ~~Exhibit~~energy 10they use.1 ~~hereto~~HEAL’s ~~and~~primary isproducts ~~incorporated~~are ~~herein~~mid-sized bywind ~~reference~~turbines, small solar panels and related controllers and inverters.

~~Effective~~On ~~February~~October 1928, ~~2018~~2016, we entered into a ~~Patent~~share ~~Purchase~~exchange ~~and~~agreement ~~License Agreement~~ with ~~Ramot~~Cohen ~~at Tel-Aviv University Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 6~~Mizrahi,~~858,007~~ ~~“Method~~a ~~and~~director ~~system for automatic classification and quantitative evaluation~~ of ~~adnexal~~our ~~masses~~company, ~~based~~whereby on ~~a cross-sectional or projectional images of~~ the ~~adnexs”~~same ~~(the~~date ~~“Ramot~~we ~~Patent”).~~issued ~~We paid $10~~4,000,000 asshares ~~consideration~~of ~~for~~our ~~the~~common ~~Ramot~~stock ~~Patent~~in ~~and~~exchange ~~agreed~~for ~~to pay royalties of one percent (1~~100%) of the ~~net~~issued ~~sales of all products sold by our company that are derived from the invention covered by the Ramot Patent, such royalties to be paid quarterly in January, April, July~~ and ~~October~~outstanding ~~from~~equity ~~sales~~interests ~~incurred~~of inEnergy ~~the previous calendar quarter~~Alliance.

~~The~~On ~~assignment~~November of1, 2016, Energy Alliance closed the ~~Ramot~~transactions ~~Patent~~contemplated ~~was~~under ~~registered~~an agreement with certain shareholders of HEAL, in which the ~~United~~shareholders ~~States~~holding ~~Patent~~80% ~~and~~of ~~Trademark~~the ~~Office~~outstanding onequity ~~March~~interests 5,of ~~2018~~HEAL sold all of their shares of HEAL to Energy Alliance.

October 1, 2019, a majority of our shareholders approved a reverse stock split on a basis of 100 old shares for one (1) new share of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding shares of common stock decreased from 15,579,749 to 155,798 shares of common stock, our authorized capital remained unchanged. The reverse split became effective with the OTC Markets at the opening of trading on January 9, 2020.13

~~Effective~~Table ~~January~~of 28, 2020, the Company amended a 20% Convertible Note originally issued on March 31, 2019 (the “Note”). The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.Contents

14As ~~Table~~a result of ~~Contents~~such transactions we became the owner of 100% of the issued and outstanding equity interests of Energy Alliance and Energy Alliance became the owner of 80% of the issued and outstanding equity interests of HEAL.

Effective ~~January~~October 284, ~~2020~~2016, ~~the~~we ~~Note~~filed ~~was~~a ~~assigned~~Certificate ~~to Evergreen Solutions Ltd., and was immediately converted for the issuance~~ of ~~54,270,000~~Dissolution ~~shares~~ of ~~common~~MJP ~~stock~~Holdings ofLtd., ~~the~~our ~~Company~~wholly-owned ~~resulting in a change of control~~subsidiary.

OnEffective ~~February~~November 328, ~~2020~~2016, ~~Cohen~~we ~~Mizrahi~~entered ~~resigned~~into as a ~~director~~Share ~~and~~Exchange asAgreement anwith ~~officer~~MJP ofLighting ~~our~~Solutions ~~company~~Ltd. ~~Dr. Mizrahi’s resignation was not the result of a disagreement between Dr. Mizrahi and our company on any matter relating to our company’s operations~~, ~~policies or practices. On February 3, 2020, David Magana Gonzalez was appointed as~~ a ~~director~~British toVirgin ~~replace~~Islands ~~Dr.~~(“BVI”) ~~Mizrahi~~corporation and heTong ~~was~~Tang ~~also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary~~ and ~~Treasurer~~Zhao ofHui ~~our~~Ma ~~company.~~(the On“Shareholders”) ~~July~~whereby ~~22,~~the ~~2020,~~parties ~~David~~exchanged ~~Magna~~100% ~~Gonzalez resigned as a director and as an officer~~ of ~~our company. Mr. Gonzalez’s resignation was not~~ the ~~result~~issued ~~of a disagreement between Mr. Gonzalez~~ and ~~our~~outstanding ~~company~~shares onof ~~any~~BVI, ~~matter~~belonging ~~relating~~ to our company’s ~~operations,~~for ~~policies~~the ortender ~~practices.~~of ~~On July 22~~5, ~~2020~~500,000 ~~Marc~~restricted ~~Applbaum~~common ~~was~~shares ~~appointed as a director to replace David Magna Gonzolez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer~~ of our company~~. On September 28~~, ~~2020,~~belonging ~~Marc~~to ~~Applbaum resigned as a director and as an officer of our company. Mr. Applbaums resignation was not~~ the ~~result~~Shareholders, ~~of a disagreement between Mr. Applbaum and our company on any matter relating~~ to our ~~company’s~~treasury ~~operations,~~for ~~policies or practices~~cancellation. On September 28, 2020, Aleksander Vucak was appointed as a director to replace Marc Applbaum and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.

On ~~October~~January 71, ~~2020~~2017, ~~Bionovate~~MJP ~~Technologies~~entered ~~Corp.~~into ~~(the~~transfer ~~“Company”)~~agreement ~~entered~~with ~~into~~Cohen aMizrahi, ~~Share~~whereby ~~Exchange~~we ~~Agreement~~transferred (100% of the ~~“Share~~issued ~~Exchange~~and ~~Agreement”)~~outstanding ~~facilitated~~equity ~~between~~interests ~~Evergreen~~of ~~Solutions,~~Energy ~~Ltd,~~Alliance afor ~~private~~consideration ~~Company~~of ~~(“Evergreen”)~~$20,000 ~~and~~for ~~Human~~past ~~Data~~services ~~AG,~~provided ato ~~private~~our ~~Switzerland~~company ~~Company~~by ~~(“Human~~Mr. ~~Data”)~~Guo.

~~Pursuant~~On toDecember ~~the~~1, ~~Share~~2017, ~~Exchange~~a ~~Agreement,~~majority inof ~~exchange~~our ~~for~~stockholders ~~the~~and ~~acquisition~~our board of ~~all~~directors ofapproved ~~the~~a ~~outstanding~~change ~~Company~~of ~~shares~~name ~~which~~of ~~Evergreen~~our ~~owns,~~company to ~~wit, 54,270,000 shares (the~~ “~~Exchange~~Bionovate ~~Shares~~Technologies Corp.”), ~~the~~and ~~Company~~a ~~will~~reverse ~~receive~~stock ~~12,500~~split ~~shares~~ of ~~Digital~~our ~~Diagnostics~~issued AGand ~~(“Digital”)~~outstanding ~~owned~~shares byof ~~Human~~common ~~Data,~~stock ~~which~~on ~~equates~~a tofifty ~~25%~~(50) ofold ~~the~~for ~~currently~~one ~~issued~~(1) ~~shares~~new ~~of Digital~~basis.

~~The~~A ~~Share~~Certificate ~~Exchange~~of ~~Agreement~~Amendment ~~contains~~was ~~customary~~filed ~~representations~~with ~~and warranties made by~~ the ~~Company,~~Nevada onSecretary ~~the~~of ~~one~~State ~~hand, and Evergreen and Human Data~~ on ~~the~~December ~~other hand~~11, ~~made~~2017 ~~solely~~with ~~for~~an ~~the~~effective ~~benefit~~date of ~~the~~December ~~other~~21, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement2017.

The ~~share~~name ~~exchange~~change ~~agreement~~and ~~gave~~reverse ~~the~~split ~~other~~became ~~party~~effective 90with ~~days~~the toOTC ~~transfer~~Markets ~~shares~~at ofthe ~~Digital~~opening toof ~~Bionovate.~~trading ~~Bionovate~~on ~~did~~December ~~not~~21, ~~receive~~2017 ~~these~~under ~~shares yet and does not own any of Digital Diagnostics as of~~ the ~~date~~symbol ~~of this report~~“BIIO”.

OnEffective ~~December~~January 411, ~~2020~~2018, 13we entered into a Patent Purchase and License Agreement with Lily Innovation Advisors Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 7,~~820~~963,959 “Automated Cryogenic Skin Treatment” (the “Lily Patent”). We paid $10,000 ~~shares~~as ~~were~~consideration ~~canceled~~for the Lily Patent, and agreed to pay royalties of one percent (1%) of the (a) net sales of all products that are derived from the invention covered under the Lily Patent and sold by our company or any licensees or transferees and (b) licensing fees, royalties or similar payments in respect of the ~~CEO~~Lily Patent received by any such entity, such royalties to be paid quarterly in January, April, July and October for all sales incurred in the previous calendar quarter.

~~Our~~The ~~corporate~~assignment ~~address~~of isthe ~~Gewerbestrasse~~Lily ~~10,~~Patent ~~Cham,~~was ~~Switzerland~~registered ~~6330.~~with Wethe doUnited ~~not~~States ~~have~~Patent aand ~~corporate~~Trademark ~~website~~Office on January 31, 2018.

WeThe doforegoing description of the Patent Purchase and License Agreement is included to provide information regarding its terms. It does not ~~have~~purport ~~any~~to ~~subsidiaries~~be a complete description and is qualified by its entirety by reference to the full text of the Patent Purchase and License Agreement, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Effective February 19, 2018, we entered into a Patent Purchase and License Agreement with Ramot at Tel-Aviv University Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 6,858,007 “Method and system for automatic classification and quantitative evaluation of adnexal masses based on a cross-sectional or projectional images of the adnexs” (the “Ramot Patent”). We ~~have~~paid ~~not~~$10,000 ~~been~~as ~~subject~~consideration for the Ramot Patent and agreed to ~~any~~pay ~~bankruptcy~~royalties of one percent (1%) of the net sales of all products sold by our company that are derived from the invention covered by the Ramot Patent, ~~receivership~~such royalties to be paid quarterly in January, orApril, ~~similar~~July ~~proceeding~~and October from sales incurred in the previous calendar quarter.

~~Current~~The ~~Business~~assignment of the Ramot Patent was registered with the United States Patent and Trademark Office on March 5, 2018.

~~Bionovate~~October ~~Technologies~~1, ~~Corp.~~2019, ~~focuses~~a onmajority ~~investments~~of ~~and~~our ~~the~~shareholders ~~marketing~~approved a reverse stock split on a basis of ~~patents~~100 ~~and~~old ~~licenses~~shares ~~which~~for ~~bring~~one ~~healthcare~~(1) ~~and~~new ~~lifestyle~~share ~~diagnostics~~of toour ~~your~~issued ~~smartphone.~~and ~~With~~outstanding ~~strong~~common ~~emphasis~~stock. onAs ~~digital~~a ~~transformation,~~result of the ~~company~~reverse ~~intends~~split, toour ~~build~~issued anand ~~FDA-approved~~outstanding ~~ecosystem~~shares of ~~medical~~common ~~devices~~stock decreased from 15,579,749 ~~biosensors~~to ~~and~~155,798 ~~mobile~~shares ~~applications~~of tocommon ~~turn~~stock, ~~tests~~our ~~that~~authorized ~~were~~capital ~~previously~~remained ~~only~~unchanged. ~~done~~The inreverse ~~physical~~split ~~labs~~became ~~into~~effective ~~tests~~with ~~that~~the ~~can~~OTC beMarkets ~~carried~~at ~~through~~the byopening ~~anyone~~of ~~with~~trading aon ~~mobile~~January ~~device~~9, 2020.

~~15 Table of Contents~~14

~~Results~~Table of ~~Operations~~Contents

~~Our~~Effective ~~operations~~January ~~for~~28, 2020, the ~~three~~Company ~~and~~amended ~~six~~a ~~ended~~20% ~~December~~Convertible Note originally issued on March 31, ~~2020~~2019 (the “Note”). The Note reduces the interest rate from 20% to 0 and ~~2019~~changes ~~are~~the ~~outlined~~conversion ~~below:~~price from $0.01 to $0.0001.

~~Three~~Effective ~~months~~January ~~ended December 31~~28, 2020, ~~compared~~the Note was assigned to ~~three~~Evergreen ~~months~~Solutions ~~ended~~Ltd., ~~December~~and 31was immediately converted for the issuance of 54,270,000 ~~2019~~shares of common stock of the Company resulting in a change of control.

	Three Months Ended
	December 31,				Change
	2020		2019		Amount			%
Revenues	$	-	$	-	$	-			-
Operating Expenses		20,688		10,950		9,738			89	%
Total other expense		11,746		34,619		(22,873	)		(66	)%
Net Loss	$	32,434	$	45,569	$	(13,135	)		(29	)%

On February 3, 2020, Cohen Mizrahi resigned as a director and as an officer of our company. Dr. Mizrahi’s resignation was not the result of a disagreement between Dr. Mizrahi and our company on any matter relating to our company’s operations, policies or practices. On February 3, 2020, David Magana Gonzalez was appointed as a director to replace Dr. Mizrahi and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On July 22, 2020, David Magna Gonzalez resigned as a director and as an officer of our company. Mr. Gonzalez’s resignation was not the result of a disagreement between Mr. Gonzalez and our company on any matter relating to our company’s operations, policies or practices. On July 22, 2020, Marc Applbaum was appointed as a director to replace David Magna Gonzolez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On September 28, 2020, Marc Applbaum resigned as a director and as an officer of our company. Mr. Applbaums resignation was not the result of a disagreement between Mr. Applbaum and our company on any matter relating to our company’s operations, policies or practices. On September 28, 2020, Aleksander Vucak was appointed as a director to replace Marc Applbaum and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.

~~For~~On ~~the~~October ~~three months ended December 31~~7, 2020 ~~and 2019~~, weBionovate ~~had~~Technologies ~~no revenue~~Corp. ~~Expenses for~~ (the ~~three~~“Company”) ~~months~~entered ~~ended~~into ~~December~~a ~~31,~~Share ~~2020~~Exchange ~~totaled~~Agreement ~~$32,434~~(the ~~resulting~~“Share inExchange aAgreement”) ~~net~~facilitated ~~loss~~between ofEvergreen ~~$32~~Solutions,~~434~~ asLtd, ~~compared to~~ a ~~net~~private ~~loss~~Company ~~of $45~~(“Evergreen”),~~569~~ ~~for~~and ~~the~~Human ~~three~~Data ~~months ended December 31~~AG, ~~2019. The decrease in net loss for the three months ended December 31, 2020 is~~ a ~~result~~private ofSwitzerland aCompany ~~decrease~~(“Human ~~in interest expense offset by an increase in professional fee~~Data”).

~~Six~~Pursuant ~~months~~to ~~ended~~the ~~December~~Share 31Exchange Agreement, ~~2020~~in ~~compared~~exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to ~~six~~wit, ~~months~~54,270,000 ~~ended~~shares ~~December~~(the 31“Exchange Shares”), ~~2019~~the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital.

	Six Months Ended
	December 31,				Change
	2020		2019		Amount			%
Revenues	$	-	$	-	$	-			-
Operating Expenses		24,310		24,362		(52	)	(0%)
Total other expense		30,998		50,583		(19,585	)		(39	)%
Net Loss	$	55,308	$	74,945	$	(19,637	)		(26	)%

The Share Exchange Agreement contains customary representations and warranties made by the Company, on the one hand, and Evergreen and Human Data on the other hand, made solely for the benefit of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement.

~~For~~The ~~the~~share ~~six~~exchange ~~months~~agreement ~~ended~~gave ~~December 31, 2020 and 2019, we had no revenue. Expenses for~~ the ~~six~~other ~~months~~party ~~ended~~90 ~~December~~days ~~31,~~to ~~2020~~transfer ~~totaled~~shares ~~$55,308 resulting in a net loss~~ of ~~$55,308~~Digital ~~as compared~~ to aBionovate. ~~net~~Bionovate ~~loss~~did ofnot ~~$74,945~~receive ~~for~~these ~~the~~shares ~~six~~yet ~~months~~and ~~ended~~does ~~December~~not ~~31,~~own ~~2019.~~any ~~The~~of ~~decrease~~Digital inDiagnostics ~~net~~as ~~loss~~of ~~for~~ the ~~six~~date ~~months ended December 31, 2020 is a result~~ of athis ~~decrease in interest expense~~report.

~~Liquidity~~On ~~and~~December ~~Capital~~4, ~~Resources~~2020, 13,820,000 shares were canceled by the CEO.

~~The~~Our ~~following~~corporate ~~table~~address ~~provides~~is ~~selected~~Gewerbestrasse ~~financial~~10, ~~data~~Cham, ~~about~~Switzerland ~~our~~6330. ~~company~~We asdo ofnot ~~December~~have ~~31,~~a ~~2020~~corporate ~~and June 30, 2020, respectively~~website.

~~Working~~We ~~Capital~~ do not have any subsidiaries.

	December 31,			June 30,			Change
	2020			2020			Amount			%
Current Assets	$	-		$	-		$	-			-
Current Liabilities	$	451,973		$	396,665			55,308			14	%
Working Capital (Deficit)	$	(451,973	)	$	(396,665	)	$	(55,308	)		14	%

We have not been subject to any bankruptcy, receivership, or similar proceeding.

16Current ~~Table of Contents~~Business

~~Cash~~Bionovate ~~Flows~~Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device.

	Six Months Ended
	December 31,
	2020		2019
Net Cash Provided by Operating Activities	$	-	$	-
Net Cash Provided by Investing Activities	$	-	$	-
Net Cash Provided by Financing Activities	$	-	$	-
Net Change in Cash During the Period	$	-	$	-

OnTable ~~December~~of ~~31, 2020, our Company’s cash balance was $0 and total assets were $0. On June 30, 2020, our Company’s cash balance was $0 and total assets were $0.~~Contents

OnResults ~~December 31, 2020, our Company had total liabilities~~ of ~~$451,973, compared with total liabilities of $396,665 as at June 30, 2020.~~Operations

OnOur ~~December~~operations ~~31,~~for ~~2020,~~the ~~our~~three ~~Company~~and ~~had~~nine ~~working~~ended ~~capital~~March ~~deficiency of $451~~31,~~973~~ ~~compared~~2021 ~~with~~and ~~working capital deficiency of $396,665 as at June 30,~~ 2020. ~~The~~are ~~increase~~outlined ~~in working capital was primarily attributed to an increase in accounts payable and accrued liabilities and due to related party.~~below:

~~Cash~~Three ~~Flow~~months ~~from~~ended ~~Operating~~March ~~Activities~~31, 2021 compared to three months ended March 31, 2020.

During the six months ended December 31, 2020, our Company provided $0 by operating activities, compared to $0 provided by operating activities during the six months ended December 31, 2019.

		Three Months Ended
		March 31,				Change
		2021		2020		Amount		%
Revenues	$	—	$	—	$	—		—
Operating Expenses		16,685		2,748		13,937		507	%
Total other expense		14,980		21,390		(6,410	)	(30)	%
Net Loss	$	31,665	$	24,138	$	7,527		31	%

~~Cash~~For ~~Flow~~the ~~from~~three ~~Investing~~months ~~Activities~~ended March 31, 2021 and 2020, we had no revenue. Expenses for the three months ended March 31, 2021 totaled $31,665 resulting in a net loss of $31,665 as compared to a net loss of $24,138 for the three months ended March 31, 2020. The increase in net loss for the three months ended March 31, 2021 is a result of an increase in professional fees offset by a decrease in interest expenses.

~~During~~Nine ~~the six~~ months ended ~~December~~March 31, ~~2020~~2021 ~~and~~compared ~~2019,~~to ~~our~~nine ~~Company~~months ~~did~~ended ~~not~~March ~~have~~31, ~~any investing activities~~2020.

Cash Flow from Financing Activities

		Nine Months Ended
		March 31,				Change
		2021		2020		Amount		%
Revenues	$	—	$	—	$	—		—
Operating Expenses		40,995		27,110		13,885		51	%
Total other expense		45,978		71,973		(25,995	)	(36)	%
Net Loss	$	86,973	$	99,083	$	(12,110	)	(12)	%

~~During~~For the ~~six~~nine months ended ~~December~~March 31, ~~2020~~2021 and ~~2019~~2020, ~~our~~we ~~Company~~had ~~did~~no ~~not~~revenue. ~~have~~Expenses ~~any~~for ~~investing~~the ~~activities~~nine months ended March 31, 2021 totaled $86,973 resulting in a net loss of $86,973 as compared to a net loss of $99,083 for the nine months ended March 31, 2020. The decrease in net loss for the nine months ended March 31, 2021 is a result of a decrease in interest expense offset by an increase in professional fees.

~~Off-Balance~~Liquidity ~~Sheet~~and ~~Arrangements~~Capital Resources

WeThe ~~have~~following notable ~~off-balance~~provides ~~sheet~~selected ~~arrangements~~financial ~~that~~data ~~have~~about ~~or are reasonably likely to have a current or future effect on~~ our ~~financial~~company ~~condition,~~as ~~changes~~of inMarch ~~financial condition~~31, ~~revenues~~2021 orand ~~expenses,~~June ~~results of operations~~30, ~~liquidity~~2020, ~~and capital expenditures or capital resources that are material to stockholders~~respectively.

~~Critical~~Working ~~Accounting Policies~~Capital

Revenue Recognition

		March 31,			June 30,			Change
		2021			2020			Amount		%
Current Assets	$	—		$	—		$	—		—
Current Liabilities	$	483,638		$	396,665			86,973		22	%
Working Capital (Deficit)	$	(483,638	)	$	(396,665	)	$	(86,973	)	22	%

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:16

·Table ~~identify~~of the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied.Contents

17Cash ~~Table of Contents~~Flows

Recent Accounting Pronouncements

		Nine Months Ended
		March 31,
		2021		2020
Net Cash Provided by Operating Activities	$	—	$	—
Net Cash Provided by Investing Activities	$	—	$	—
Net Cash Provided by Financing Activities	$	—	$	—
Net Change in Cash During the Period	$	—	$	—

WeOn ~~have~~March ~~implemented~~31, ~~all~~2021, ~~new~~our ~~accounting~~Company’s ~~pronouncements~~cash ~~that~~balance ~~are~~was in$0 ~~effect~~ and ~~that~~total ~~may~~assets ~~impact~~were ~~our~~$0. ~~financial~~On ~~statements~~June ~~and~~30, ~~does~~2020, ~~not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on~~ our ~~financial~~Company’s ~~position~~cash orbalance ~~results~~was of$0 ~~operations. Our company regularly reviews~~ and ~~analyses~~total ~~the~~assets ~~recent~~were ~~accounting pronouncements~~$0.

~~Item~~On 3.March ~~Quantitative~~31, ~~and~~2021, ~~Qualitative~~our ~~Disclosures~~Company ~~About~~had ~~Market~~total ~~Risk~~liabilities of $483,638, compared with total liabilities of $396,665 as at June 30, 2020.

AsOn aMarch ~~“smaller~~31, ~~reporting~~2021, ~~company”~~our Company had working capital deficiency of $483,638 wecompared ~~are~~with ~~not~~working ~~required~~capital deficiency of $396,665 as at June 30, 2020. The increase in working capital was primarily attributed to ~~provide~~an ~~the~~increase ~~information~~in ~~required~~accounts bypayable ~~this~~and ~~Item~~accrued liabilities and due to related party.

~~Item~~Cash 4.Flow ~~Controls~~from ~~and~~Operating ~~Procedures~~Activities

~~Evaluation~~During ofthe ~~Disclosure~~nine ~~Controls~~months ~~and~~ended ~~Procedures~~March 31, 2021, our Company provided $0 by operating activities, compared to $0 provided by operating activities during the nine months ended March 31, 2020.

~~Our~~Cash ~~management~~Flow isfrom ~~responsible~~Investing for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.Activities

AnDuring ~~evaluation was conducted under~~ the ~~supervision~~nine ~~and~~months ~~with~~ended ~~the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of~~ March 31, ~~2020.~~2021 ~~Based~~and ~~on that evaluation~~2020, our ~~management~~Company ~~concluded~~did ~~that our disclosure controls and procedures were~~ not ~~effective~~have asany ofinvesting such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and formsactivities. Such officer also confirmed that there was no change in our internal control over financial reporting during the period ended March 31, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

~~Changes~~Cash inFlow ~~Internal~~from ~~Control~~Financing ~~Over Financial Reporting~~Activities

~~There~~During ~~have been no changes in our internal control over financial reporting that occurred during~~ the ~~quarter~~nine months ended ~~December~~March 31, ~~2020,~~2021 ~~that~~and ~~have materially affected~~2020, orour ~~are~~Company ~~reasonably~~did ~~likely~~not tohave ~~materially~~any ~~affect,~~investing ~~our internal control over financial reporting~~activities.

18Off-Balance ~~Table~~Sheet ~~of Contents~~Arrangements

~~PART~~We IIhave no off-balance ~~OTHER~~sheet ~~INFORMATION~~arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

~~Item~~Critical 1.Accounting ~~Legal Proceedings~~Policies

WeRevenue know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.Recognition

~~Item~~Revenues 1Aare recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. ~~Risk~~The ~~Factors~~Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

As· identify the contract with a ~~“smaller~~customer; ~~reporting~~· ~~company”,~~identify wethe ~~are~~performance ~~not~~obligations ~~required~~in the contract; · determine the transaction price; · allocate the transaction price to ~~provide~~performance obligations in the ~~information~~contract; ~~required~~and by· ~~this~~recognize ~~Item~~revenue as the performance obligation is satisfied.

~~Item 2. Unregistered Sales of Equity Securities and Use of Proceeds~~17

~~None.~~Table of Contents

~~Item~~Recent 3.Accounting ~~Defaults Upon Senior Securities~~Pronouncements

~~None~~We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations. Our company regularly reviews and analyses the recent accounting pronouncements.

Item 43. ~~Mine~~Quantitative ~~Safety~~and Qualitative Disclosures About Market Risk

~~Not~~As ~~Applicable~~a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 54. ~~Other~~Controls ~~Information~~and Procedures

~~None~~Evaluation of Disclosure Controls and Procedures

19Our ~~Table~~management is responsible for establishing and maintaining a system of ~~Contents~~disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

~~Item~~An 6evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020. ~~Exhibits~~Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the period ended March 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002
(32)		Section 1350 Certifications
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002
101*		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

Changes in Internal Control Over Financial Reporting

*There ~~Filed~~have ~~herewith~~been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

** XBRL Information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 ~~of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.~~

20 Table of Contents

~~SIGNATURES~~ PART II - OTHER INFORMATION

In ~~accordance~~Item ~~with~~1. ~~Section~~Legal ~~13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Proceedings

		BIONOVATE TECHNOLOGIES CORP.
		(Registrant)
Dated: January 28, 2021		/s/ Aleksander Vucak
		Aleksander Vucak
		President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

21 Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None

Table of Contents

Item 6. Exhibits

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002
(32)		Section 1350 Certifications
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002
101*		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** XBRL Information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BIONOVATE TECHNOLOGIES CORP.
		(Registrant)

Dated: May 17, 2021		/s/ Aleksander Vucak
		Aleksander Vucak
		President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · Bionovate Technologies Corp.